Skip header and navigation

Refine By

73 records – page 1 of 8.

Acute leukemia in children: experience in Saskatchewan in 1966-72.

https://arctichealth.org/en/permalink/ahliterature252007
Source
Can Med Assoc J. 1975 Aug 23;113(4):295-8
Publication Type
Article
Date
Aug-23-1975
Author
J B McSheffrey
A. Naidoo
W E Hirte
Source
Can Med Assoc J. 1975 Aug 23;113(4):295-8
Date
Aug-23-1975
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Antineoplastic Agents - therapeutic use
Blood Transfusion
Child
Cyclophosphamide - therapeutic use
Cytarabine - therapeutic use
Daunorubicin - therapeutic use
Drug Therapy, Combination
Follow-Up Studies
Hematopoietic Stem Cells
Humans
Leukemia - drug therapy - epidemiology - therapy
Leukemia, Lymphoid - drug therapy - therapy
Palliative Care
Prednisone - therapeutic use
Saskatchewan
Vincristine - therapeutic use
Abstract
In 1966-72 in Saskatchewan there was a significant improvement in survival of patients up to 16 years old with acute leukemia treated intensively. The rate of complications was low. Attention to the emotional needs of the patients and parents and formation of parent mutual-support groups improved the acceptibility of intensive therapy.
Notes
Cites: JAMA. 1971 Apr 26;216(4):648-525279904
Cites: Clin Pediatr (Phila). 1971 Oct;10(10):571-55289094
Cites: Cancer. 1963 May;16:656-6413934544
Cites: Lancet. 1973 Oct 13;2(7833):8624126675
Cites: Blood. 1971 Mar;37(3):272-814322483
Cites: Blood. 1972 Jun;39(6):759-704337622
Cites: Arch Dis Child. 1972 Jun;47(253):344-544504035
Cites: Biometrics. 1973 Sep;29(3):579-844793138
Cites: J Pediatr. 1968 Mar;72(3):399-4085237796
Cites: Can Med Assoc J. 1969 Oct 4;101(7):87-905259437
Cites: Pediatrics. 1970 Feb;45(2):191-35263280
PubMed ID
50120 View in PubMed
Less detail

Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies.

https://arctichealth.org/en/permalink/ahliterature24760
Source
Lancet. 1991 Aug 31;338(8766):535-8
Publication Type
Article
Date
Aug-31-1991
Author
R. Arriagada
L E Rutqvist
Author Affiliation
Institut Gustave-Roussy, Villejuif, France.
Source
Lancet. 1991 Aug 31;338(8766):535-8
Date
Aug-31-1991
Language
English
Publication Type
Article
Keywords
Adult
Aged
Analysis of Variance
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy - epidemiology - radiotherapy
Combined Modality Therapy
Comparative Study
Cyclophosphamide - therapeutic use
Drug Administration Schedule
Drug Evaluation
Female
Fluorouracil - therapeutic use
Humans
Incidence
Methotrexate - therapeutic use
Middle Aged
Neoplasms, Multiple Primary - prevention & control
Radiotherapy Dosage
Registries
Research Support, Non-U.S. Gov't
Sweden - epidemiology
Tamoxifen - administration & dosage - therapeutic use
Time Factors
Abstract
Adjuvant chemotherapy is increasingly being given to patients with early breast cancer. Long-term follow-up studies suggest a higher frequency of secondary tumours, especially leukaemias, among women receiving such cytotoxic drugs. We studied the frequency of new primary malignancies in 1113 patients with early breast cancer who had been included in a randomised trial to compare chemotherapy as an adjunct to primary surgery with adjuvant locoregional radiotherapy. The estimated rate of new primary malignancies at ten years was significantly lower (p less than 0.0003) in the chemotherapy group (1%) than in the radiotherapy group (6%). The corresponding rate among 1986 patients treated with surgery alone was 5%. Our findings suggest that adjuvant chemotherapy in early breast cancer may protect against the development of new primary tumours in the first ten years of follow-up.
Notes
Comment In: Lancet. 1991 Oct 5;338(8771):885-61681236
PubMed ID
1678800 View in PubMed
Less detail

Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia.

https://arctichealth.org/en/permalink/ahliterature20809
Source
Eur J Cancer. 1999 Apr;35(4):634-40
Publication Type
Article
Date
Apr-1999
Author
A C Martens
A. Hagenbeek
Author Affiliation
Department of Haematology, Jordan Laboratory, University Hospital Utrecht, The Netherlands. a.martens@lab.azu.nl
Source
Eur J Cancer. 1999 Apr;35(4):634-40
Date
Apr-1999
Language
English
Publication Type
Article
Keywords
Amifostine - administration & dosage
Animals
Antineoplastic Agents, Alkylating - therapeutic use
Bone Marrow Transplantation - methods
Combined Modality Therapy
Cyclophosphamide - therapeutic use
Dose-Response Relationship, Drug
Leukemia, Myelocytic, Acute - therapy
Male
Radiation-Protective Agents - administration & dosage
Rats
Rats, Inbred Strains
Survival Analysis
Whole-Body Irradiation
Abstract
The in vivo effect of the radiochemoprotectant Amifostine on the therapeutic efficacy of marrow ablative treatment with cyclophosphamide (CP) and total body irradiation (TBI) followed by bone marrow transplantation (BMT) was studied in normal rats as well as in the Brown Norway rat acute myelocytic leukaemia (BNML) model. In normal rats, when the dose of TBI was escalated and the CP dose was kept constant, pretreatment with Amifostine yielded a positive dose modification factor of 1.26. No significant improvement was found after Amifostine pretreatment when the TBI dose was kept constant and CP dose escalated. When leukaemic rats received CP as the only antileukaemia treatment, Amifostine pretreatment did not lead to a reduction in the antileukaemic efficacy of CP, although protection against treatment-related mortality was observed. In the CP only groups, 9 out of 40 animals died of treatment-related toxicity, compared with none of the 40 animals in the Amifostine pretreatment groups. When applying the maximum tolerated treatment of CP and TBI in various combinations to leukaemic rats, 25 out of 36 rats died from treatment-related toxicity, whilst pretreatment with Amifostine reduced this to 11 out of 36, (P = 0.002). Of those animals which survived the CP + TBI conditioning treatment, 10 out of 25 in the Amifostine pretreatment group were cured, versus 8/11 in the CP + TBI only control group (P = 0.146). In conclusion, incorporation of Amifostine as a radiochemoprotectant in a marrow-ablative conditioning regimen allows the use of escalated doses of chemoradiotherapy without reducing the antileukaemic efficacy.
PubMed ID
10492639 View in PubMed
Less detail

Antimetastatic effect of thymus-dependent antigen (sheep erythrocytes) in C57BL/6 mice with Lewis carcinoma.

https://arctichealth.org/en/permalink/ahliterature17464
Source
Bull Exp Biol Med. 2004 Jun;137(6):578-80
Publication Type
Article
Date
Jun-2004
Author
M D Mosienko
V S Mosienko
G I Solyanik
N G Kovalenko
Author Affiliation
R. E. Kavetskii Institute of Experimental Pathology, Oncology, and Radiobiology, National Academy of Sciences of Ukraine, Kiev, Russia. gis@onconet.kiev.ua
Source
Bull Exp Biol Med. 2004 Jun;137(6):578-80
Date
Jun-2004
Language
English
Publication Type
Article
Keywords
Animals
Antigens - immunology - therapeutic use
Antineoplastic Agents, Alkylating - therapeutic use
Carcinoma, Lewis Lung - drug therapy - immunology - pathology
Cyclophosphamide - therapeutic use
Female
Immunosuppressive Agents - therapeutic use
Mice
Mice, Inbred C57BL
Neoplasm Metastasis
Sheep
Abstract
We revealed an antimetastatic effect of thymus-dependent corpuscular antigen (sheep erythrocytes) injected intravenously or intraperitoneally in sensitizing or high doses alone or in a complex with a course dose of cyclophosphamide to C57Bl/6 mice with Lewis carcinoma. Injection of the antigen appreciably reduced the number and volume of Lewis carcinoma metastases in the lungs, notably increased the therapeutic effect of cyclophosphamide, and restored hemopoiesis, particularly, the red blood stem suppressed by the tumor process and cytostatic treatment. The growth of primary tumors virtually did not change. High dose of sheep erythrocytes was more effective.
PubMed ID
15455090 View in PubMed
Less detail

Antitumor and antimetastatic activity of fucoidan, a sulfated polysaccharide isolated from the Okhotsk Sea Fucus evanescens brown alga.

https://arctichealth.org/en/permalink/ahliterature87782
Source
Bull Exp Biol Med. 2007 Jun;143(6):730-2
Publication Type
Article
Date
Jun-2007
Author
Alekseyenko T V
Zhanayeva S Ya
Venediktova A A
Zvyagintseva T N
Kuznetsova T A
Besednova N N
Korolenko T A
Author Affiliation
Institute of Physiology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk
Source
Bull Exp Biol Med. 2007 Jun;143(6):730-2
Date
Jun-2007
Language
English
Russian
Publication Type
Article
Keywords
Antineoplastic Agents, Phytogenic - therapeutic use
Cathepsin B - metabolism
Cyclophosphamide - therapeutic use
Cysteine Endopeptidases - metabolism
Drug Synergism
Fucus - chemistry
Lung Neoplasms - secondary
Mice
Mice, Inbred C57BL
Neoplasm Metastasis - drug therapy
Neoplasm Transplantation
Neoplasms, Experimental - enzymology
Polysaccharides - therapeutic use
Sulfuric Acid Esters - therapeutic use
Cathepsins - metabolism
Cathepsin D - metabolism
Abstract
Antitumor and antimetastatic activities of fucoidan, a sulfated polysaccharide isolated from Fucus evanescens (brown alga in Okhotsk sea), was studied in C57Bl/6 mice with transplanted Lewis lung adenocarcinoma. Fucoidan after single and repeated administration in a dose of 10 mg/kg produced moderate antitumor and antimetastatic effects and potentiated the antimetastatic, but not antitumor activities of cyclophosphamide. Fucoidan in a dose of 25 mg/kg potentiated the toxic effect of cyclophosphamide.
PubMed ID
18239813 View in PubMed
Less detail

Assessment of reproductive history in systemic sclerosis.

https://arctichealth.org/en/permalink/ahliterature154487
Source
Arthritis Rheum. 2008 Nov 15;59(11):1661-4
Publication Type
Article
Date
Nov-15-2008
Author
Sasha Bernatsky
Marie Hudson
Janet Pope
Evelyne Vinet
Janet Markland
David Robinson
Niall Jones
Peter Docherty
Maysan Abu-Hakima
Sharon Leclercq
James Dunne
Douglas Smith
Jean-Pierre Mathieu
Nader Khalidi
Evelyn Sutton
Murray Baron
Author Affiliation
McGill University, Montreal, Quebec, Canada. sasha.bernatsky@mail.mcgill.ca
Source
Arthritis Rheum. 2008 Nov 15;59(11):1661-4
Date
Nov-15-2008
Language
English
Publication Type
Article
Keywords
Adult
Antirheumatic Agents - therapeutic use
Birth rate
Canada
Cohort Studies
Cyclophosphamide - therapeutic use
Female
Follow-Up Studies
Humans
Reproduction - physiology
Reproductive history
Scleroderma, Systemic - drug therapy - physiopathology
Abstract
To assess the number of live births in women whose systemic sclerosis (SSc) onset occurred during their reproductive years, and to compare this with general population rates.
Within the Canadian Scleroderma Research Group cohort, we identified 320 women whose SSc symptoms began prior to age 50 years. We determined the number of children born in the years following first onset of symptoms. We summed the years of followup from the time of first symptoms in subjects up to age 50 years (or oldest age attained, if the subject was age
PubMed ID
18975360 View in PubMed
Less detail

Augmentation of suppression in cyclophosphamide-treated rats bearing allogeneic skin implants in the anterior chamber of the eye.

https://arctichealth.org/en/permalink/ahliterature51390
Source
Invest Ophthalmol Vis Sci. 1985 Sep;26(9):1230-5
Publication Type
Article
Date
Sep-1985
Author
J B Grogan
D S Subba Rao
S E Henry
Source
Invest Ophthalmol Vis Sci. 1985 Sep;26(9):1230-5
Date
Sep-1985
Language
English
Publication Type
Article
Keywords
Animals
Anterior Chamber - immunology - surgery
Cyclophosphamide - therapeutic use
Female
Graft Rejection - drug effects
Isoantigens
Rats
Rats, Inbred Strains
Research Support, U.S. Gov't, P.H.S.
Skin Transplantation
Abstract
This study shows that alloantigen presentation via the anterior chamber (AC) of the eye coupled with a single high dose cyclophosphamide (CP) (100 mg/kg) treatment effectively suppresses the skin graft rejection reaction of the recipient. Lewis (Le) rats bearing allogeneic Brown Norway (BN) skin implants in the AC of the eye demonstrate a modest increase in the survival time of orthotopic BN skin grafts. A slight prolongation of the survival of orthotopic BN skin grafts was also demonstrated in nonimplant or syngeneic implant-bearing Le recipients which received a single injection of a large dose of CP. Augmentation of suppression was evident in rats which were treated with a single dose of 75 mg/kg CP but not 25 mg/kg. The augmentation of suppression was evident when CP treatment and skin grafting of the recipient occurred on either 0, 7, or 14 days postimplantation. Recipient splenectomy did not interfere with the augmentation of suppression.
PubMed ID
3897115 View in PubMed
Less detail

BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML).

https://arctichealth.org/en/permalink/ahliterature26987
Source
Leuk Res. 1983;7(4):547-55
Publication Type
Article
Date
1983
Author
A. Hagenbeek
A C Martens
Source
Leuk Res. 1983;7(4):547-55
Date
1983
Language
English
Publication Type
Article
Keywords
Animals
BCG Vaccine - therapeutic use
Cyclophosphamide - therapeutic use
Immunotherapy
Leukemia, Myelocytic, Acute - pathology - therapy
Rats
Research Support, Non-U.S. Gov't
Spleen - pathology
Abstract
The effect of a single injection of Pasteur BCG on the growth of a myelocytic leukemia transplantable in the Brown Norway rat (BNML) was studied. BCG (3.0 mg i.v.) caused a 6-fold increase in spleen weight with marked granuloma formation. After aspecific immunostimulation the TD50 for leukemic cells increased from 38.8 to 302.2 cells. Cyclophosphamide (100 mg/kg) given 48 h prior to BCG did not influence the anti-tumor immune response. However, cyclophosphamide injected after BCG partly abolished its activity. After high-dose chemo-radiotherapy of leukemic rats BCG significantly hampered the outgrowth of residual leukemic cells. Relapse from leukemia could even be avoided completely when BCG was injected after cyclophosphamide (100 mg/kg) and total body irradiation (7.0 Gy) followed by isologous bone marrow transplantation. These results are discussed in relation with the tumor load at the time of maximal immunostimulation. Finally, the data are extrapolated to those of the many controversial clinical studies.
PubMed ID
6578394 View in PubMed
Less detail

73 records – page 1 of 8.